Parthenogenetic mosaicism: generation via second polar body retention and unmasking of a likely causative PER2 variant for hypersomnia by Masunaga Yohei et al.
Parthenogenetic mosaicism: generation via
second polar body retention and unmasking of a
likely causative PER2 variant for hypersomnia
著者 Masunaga Yohei, Kagami Masayo, Kato Fumiko,
Usui Takeshi, Yonemoto Takako, Mishima Kazuo,













Masunaga et al. Clin Epigenet           (2021) 13:73  
https://doi.org/10.1186/s13148-021-01062-0
RESEARCH
Parthenogenetic mosaicism: generation 
via second polar body retention and unmasking 
of a likely causative PER2 variant 
for hypersomnia
Yohei Masunaga1, Masayo Kagami2, Fumiko Kato1, Takeshi Usui3, Takako Yonemoto4, Kazuo Mishima5, 
Maki Fukami2, Kazushi Aoto6, Hirotomo Saitsu6 and Tsutomu Ogata1,7*  
Abstract 
Background: Parthenogenetic mosaicism is an extremely rare condition identified only in five subjects to date. The 
previous studies indicate that this condition is mediated by parthenogenetic activation and is free from a specific 
phenotype ascribed to unmaking of a maternally inherited recessive variant in the parthenogenetic cell lineage.
Results: We examined a 28-year-old Japanese 46,XX female with Silver-Russell syndrome and idiopathic hypersom-
nia. The results revealed (1) predominance of maternally derived alleles for all the differentially methylated regions 
examined; (2) no disease-related copy-number variant; (3) two types of regions for all chromosomes, i.e., four BAF 
(B-allele frequency) band regions with single major microsatellite peaks of maternal origin and single minor micro-
satellite peaks of non-maternal (paternal) origin, and six BAF band regions with single major microsatellite peaks of 
maternal origin and two minor microsatellite peaks of maternal and non-maternal (paternal) origin; (4) an unmasked 
extremely rare PER2 variant (c.1403G>A:p.(Arg468Gln)) with high predicted pathogenicity; (5) mildly affected local 
structure with altered hydrogen bonds of the p.Arg468Gln-PER2 protein; and (6) nucleus-dominant subcellular distri-
bution of the p.Arg468Gln-PER2 protein.
Conclusions: The above findings imply that the second polar body retention occurred around fertilization, resulting 
in the generation of the parthenogenetic cell lineage by endoreplication of a female pronucleus and the normal cell 
lineage by fusion of male and female pronuclei, and that the homozygous PER2 variant in the parthenogenetic cells is 
the likely causative factor for idiopathic hypersomnia.
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Background
Normal mammalian development requires both maternal 
and paternal genomes, because of the presence of multi-
ple imprinted genes [1]. Thus, parthenogenetic mammals 
are incompatible with life because of absent expression 
of paternally expressed genes and excessive expression of 
maternally expressed genes, and androgenetic mammals 
are also lethal because of absent expression of maternally 
expressed genes and excessive expression of paternally 
expressed genes. However, such mammals could be via-
ble in the presence of a co-existing biparental cell lineage. 
Indeed, parthenogenetic and androgenetic mosaicisms 
have been identified in the human [2–7].
To our knowledge, parthenogenetic mosaicism has 
been identified in five patients [2–6]. Molecular data 
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informative for the assessment of the generation mecha-
nism invariably imply that parthenogenetic activation has 
taken place around the time of fertilization, resulting in 
the generation of the 46,XX parthenogenetic cell lineage 
by endoreplication of a female pronucleus and the bipa-
rental cell lineage by fusion of male and female pronu-
clei [2, 4–6]. Thus, although other mechanisms such as 
retention of second polar body and failure of the paternal 
pronucleus to duplicate, followed by endoreplication of a 
female pronucleus and fusion of biparentally derived pro-
nuclei, have been assumed [6], there is no report describ-
ing such generation mechanisms. Furthermore, while 
such patients frequently exhibit growth failure with some 
Silver-Russell syndrome (SRS) features [2–6], no specific 
phenotype ascribed to unmasking of a recessive patho-
genic variant(s) of maternal origin in the parthenogenetic 
cell lineage has been described, probably due to the buff-
ering effect of a co-existing paternally derived wildtype 
(WT) allele or the absence of such a variant(s) in the pre-
viously reported patients.
Here, we report parthenogenetic mosaicism mediated 
by second polar body retention and an unmasked PER2 
(period circadian regulator 2) variant in a female with 
SRS and idiopathic hypersomnia (IH).
Results
Case report
This Japanese female was conceived naturally and was 
born at 42  weeks of gestation after an uncomplicated 
pregnancy and delivery. The parents were both 29 years 
of age at her birth and were non-consanguineous and 
healthy, with the paternal height of 168  cm (− 0.5 SD) 
and the maternal height of 156 cm (− 0.4 SD). The elder 
brother was also healthy.
She exhibited SRS-compatible clinical features satisfy-
ing the Netchine-Harbison criteria [8] in infancy to early 
childhood (Table 1 and Fig. 1a). She also exhibited overt 
hypotonia and borderline developmental delay: she con-
trolled her head at six months of age, sat without sup-
port at nine months of age, walked without support at 
23 months of age, and spoke single words at two years of 
age. She received growth hormone therapy for short stat-
ure from 6 to 12 years of age, and gonadotropin releasing 
hormone analog therapy for central precocious puberty 
with menarche at 7.5 years of age (the menarchial age in 
Japanese girls, 12.25 ± 1.25  years) from 7 to 12  years of 
age. She also had hypersomnia from childhood and trun-
cal obesity and oligomenorrhea from late teens.
At 28  years of age, she was referred to us for the 
genetic studies of SRS. At that time, she manifested 
short stature, relative macrocephaly, hemihypoplasia, 
truncal obesity, borderline intellectual disability, and 
mild hypotonia, together with several other features 
(Table  1 and its Footnote-6 and Fig.  1a). Biochemi-
cal and radiological findings were grossly normal, 
except for mild fatty liver, low blood estradiol (24  pg/
mL) (reference values: follicular phase 29 – 197 pg/mL, 
luteal phase 44 – 492 pg/mL), and hypoplastic ovaries 
and uterus. Her karyotype was 46,XX in all the 100 
lymphocytes examined. Estrogen and progesterone 
replacement therapy was started, successfully inducing 
menses.
We performed detailed examinations for hypersomnia 
which was specific to her and compromised her quality of 
life. She had prolonged nocturnal sleep, daytime sleepi-
ness, unrefreshing naps, and difficulty in awaking, and 
had no episode suggestive of cataplexy or severe snoring. 
Orexin concentration was 242  pg/mL (reference value, 
> 110  pg/mL) in the cerebrospinal fluid, and HLA typ-
ing indicated DQB1*03:01/DQB1*06:01 genotype and 
excluded the narcolepsy-associated DQB1*06:02 allele 
[9]. Polysomnography (PSG) revealed a total sleep time of 
505 min (age-matched average sleep time, 460 min) with 
normal sleep structure, apnea-hypoxia index of 2.9/h (ref-
erence value, < 5/h), and 3% oxygen desaturation index of 
5.3/hour (reference value, < 15/h). Multiple sleep latency 
test (MSLT) showed remarkably short sleep latency of 
1.5 min, and no sleep onset rapid eye movement period 
(SOREMP). These findings, especially the sleep-related 
symptoms and the combination of sleep latency of 
< 8  min and no SOREMP on PSG/MSLT, indicated IH 
rather than sleep apnea syndrome, narcolepsy (both type 
1 with cataplexy and type 2 without cataplexy), and cir-
cadian rhythm sleep-wake disorders such as advanced 
or delayed sleep-wake phase disorder [9–11]. After thor-
ough consultation, she received modafinil treatment [11], 
which appeared effective for the first ~  two months but 
became obviously ineffective thereafter. Thus, it was dis-
continued after six months of therapy.
Sample preparations
We obtained leukocyte gDNA samples of the patient, the 
mother, and the brother, and salivary cell gDNA sample 
of the patient. Unfortunately, paternal sample was not 
available, because he had been deceased.
Methylation analysis
Pyrosequencing analysis showed abnormal, but not 
extremely skewed (e.g., < 10% or > 90%), methylation 
indices (MIs, the ratios of methylated clones) not only for 
SRS-related differentially methylated regions (DMRs) but 
also for other imprinting disease-related DMRs (Fig. 1b). 
The MIs were consistent with the predominance of 
maternally derived DMRs.
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Genomewide array‑based analysis
CytoScan HD revealed no known pathogenic copy-
number variant (CNV) or CNV of unknown signifi-
cance absent from public databases. B allele frequency 
(BAF) analysis showed two types of regions for all chro-
mosomes, i.e., one type of regions with four bands for 
different BAFs (0.00, ~ 0.15, ~ 0.85, and 1.00) and the 
other type of regions with six bands for different BAFs 
(0.00, ~ 0.15, ~ 0.30, ~ 0.70, ~ 0.85, and 1.00) (Fig. 1c and 
Additional file  1: Fig. S1). The pericentromeric portions 
were invariably composed of four BAF band regions.
Table 1 Clinical findings in six cases with parthenogenetic mosaicism
Footnote-1: Bifid uvula and submucous cleft palate. Footnote-2: Clinodactyly, syndactyly of toes, and down-turned mouth. Footnote-3: Skin pigmentation, hearing 
loss, and childhood obesity. Footnote-4: Triangular face, 5th finger clinodactyly, and horseshoe kidney. Footnote-5: Short nasal bone, single umbilical artery, and 
diaphragmatic hernia (left). Footnote-6: Bilateral myopia, left hearing loss, hypoplastic and low-set ears, micrognathia, irregular teeth, small hands and feet, 5th finger 
shortening and clinodactyly, big and laterally deviated toes, café au lait spots, truncal obesity, precocious puberty, and hypersomnia
OFC, occipitofrontal circumference; SDS, standard deviation score; BMI, body mass index; L, leukocytes; SF, skin fibroblasts; PA, parthenogenetic activation; ER, 
endoreplication; PB-2, second polar body; and DQ, developmental quotient
a Birth OFC SDS ≥ 1.5 above birth length or weight SDS
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
<Parthenogenetic mosaicism>
Karyotype 46,XX/46,XY 46,XX/46,XY/69,XXY 46,XX/46,XY 45,X/46,XX 46,XX/47,XXX 46,XX
Parthenogenetic cells 46,XX 46,XX 46,XX 46,XX 46,XX 46,XX
Non-parthenogenetic cells 46,XY 46,XY & 69,XXY 46,XY 45,X 47,XXX 46,XX
Frequency of parthenoge-
netic cells
> 98% (L) ~ 100% (L) 0% (L) 84% (L) 42% (Amniocytes) 70% (L)
< 5% (SF) ~ 0% (SF) 45% (SF) 56% (Saliva) 67% (Saliva)
Generation mechanism PA and ER Unknown PA and ER PA and ER PA and ER PB-2 retention and ER
<Clinical features>
Present age 1.2 years Unknown Unknown 34 years 18 weeks of gestation 28 years
Phenotypic/social sex Male Male Male Female Unknown Female
Prenatal growth failure – + Unknown + + +
Birth length — cm Unknown Unknown Unknown 44.0 (− 3.1 SD) … (Fetus) 42.0 (− 4.6 SD)
Birth weight — kg 3.36 (− 0.5 SD) < 3rd percentile Unknown 2.10 (− 2.9 SD) … (Fetus) 2.41 (− 3.0 SD)
Birth OFC — cm Unknown 50th percentile Unknown 30.5 (− 2.3 SD) … (Fetus) Unknown
Postnatal growth failure Unknown – Unknown + … (Fetus) +
Present height — cm Unknown 25 percentile Unknown 125.0 (− 6.2 SD) … (Fetus) 146.9 (− 2.1 SD)
Present weight — kg Unknown Unknown Unknown 37.5 (− 2.0 SD) … (Fetus) 60.4 (+ 0.9 SD)
Present OFC — cm Unknown Unknown Unknown 51.2 (− 2.8 SD) … (Fetus) 55.6 (− 0.1 SD)
Intellectual disability + (Mild) + (Moderate) + + (DQ 56) … (Fetus) ± 
Hypotonia Unknown Unknown Unknown + … (Fetus) +
Disorder of sex development + (46,XX DSD) + (Genital anoma-
lies)
Unknown – … (Fetus) –
<SRS: Netchine-Harbison scoring system features>[7]
Birth length and/or weight ≤  
− 2 SDS
– + (probably) Unknown + … (Fetus) +
Relative macrocephaly at 
 birtha
Unknown + (probably) Unknown + … (Fetus) Unknown
Postnatal height (at 
~ 2 years) ≤  − 2 SDS
Unknown – Unknown + … (Fetus) +
Prominent forehead 
(1–3 years)
Unknown + (probably) Unknown + … (Fetus) +
Body asymmetry + + + + … (Fetus) +
Feeding difficulties and/or 
low BMI
Unknown Unknown Unknown Unknown … (Fetus) +
Other features Footnote-1 Footnote-2 Footnote-3 Footnote-4 Footnote-5 Footnote-6
References [2] [3] (Patient 11) [4] (Patient 30) [5] [6] This patient
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Microsatellite analysis
Microsatellite analysis delineated a different pat-
tern between four and six BAF band regions (Fig.  1d 
and Additional file  1: Table  S1). For loci on four BAF 
band regions (shown in blue), informative results were 
obtained for several loci, showing two peaks in the 
patient, one major peaks consistent with maternal iso-
disomy and one minor peaks of non-maternal (paternal) 
origin. For loci on six BAF band regions (shown in red), 
informative results were also obtained for several loci, 
showing three peaks in the patient, one major peaks con-
sistent with maternal isodisomy and two minor peaks 
of maternal and non-maternal (paternal) origin. The 
frequency of the parthenogenetic cells was calculated 
as 70% in leukocytes and 67% in salivary cells, using 
informative microsatellite data for loci on four BAF band 
regions (e.g., D2S2211) (Additional file 1: Note).
Whole exome sequencing
Whole exome sequencing was performed, to iden-
tify an underlying genetic factor(s) for IH specific 
to this patient. Consequently, a missense variant 
on the third nuclear export signal (NES3) of PER2 
(NM_022817.2:c.1403G>A:p.(Arg468Gln)) (https:// 
www. ncbi. nlm. nih. gov/ genba nk) was identified as 
the most likely underlying factor for IH, because of its 
extreme rarity in the public and in-house databases 
(registered in gnomeAD_exome_EAS in a heterozygous 
condition with the allele frequency of 0.0001604), high 
predicted pathogenicity, and relevance to the circadian 
rhythm [12] (Fig. 2a–c). This variant was detected in 55 
of 66 reads (83.3%) in this patient and in 25 of 52 reads 
(48.0%) in the mother. The frequency was well consist-
ent with the genomic position of PER2 on the four BAF 
band region where BAF is assumed to be ~ 85% (Fig. 2d). 
No other rare and pathogenic variants were identified in 
sleep-related genes [12].
Protein modelling analysis
In the mouse crystal structure of a PAS domain fragment 
(Protein Data bank ID code: 3GDI), p.Arg466Gln, which 
corresponds to p.Arg468Gln in the human, was evaluated 
to mildly affect the local protein structure and hydrogen 
bonds (Fig. 2e).
Subcellular distribution analysis
Since this variant resided at NES3, we compared sub-
cellular distribution pattern between the GFP-labelled 
WT-PER2 and p.Arg468Gln-PER2 proteins. The 
p.Arg468Gln-PER2 protein was mildly but significantly 
more localized to the nucleus than the WT-PER2 protein 
(Fig. 2f ).
Discussion
Molecular studies indicate that this patient had par-
thenogenetic mosaicism. It is inferred that the second 
polar retention occurred around the time of fertilization, 
resulting in the generation of the parthenogenetic cell 
lineage by endoreplication of a female pronucleus and the 
normal cell lineage by fusion of male and female pronu-
clei (Fig. 1e) [6] (thus, in a strict sense, this condition is 
neither mosaicism caused by a mitotic error of a single 
zygote nor chimerism resulting from the fusion of two 
different zygotes). In this case, this patient is assumed 
to have three haploid sets of maternal origin (two in the 
parthenogenetic cell lineage and one in the biparental 
cell lineage) consisting of homozygous and heterozygous 
regions, with pericentromeric portions being composed 
of homozygous regions, together with one haploid set 
of paternal origin (Fig.  1e). This explains why the MIs 
were outside the normal range but were not extremely 
skewed, and why this patient had not only four BAF band 
regions with single major microsatellite peaks of mater-
nal origin and single minor microsatellite peaks of non-
maternal (paternal) origin but also six BAF band regions 
(See figure on next page.)
Fig. 1 Clinical and molecular findings of this patient. a Photographs of this patient at one and 28 years of age. b Methylation indices for imprinting 
disease-related DMRs, obtained by pyrosequencing. Normally, the H19/IGF2:IG-DMR, MEG3/DLK1:IG-DMR, and MEG3:TSS-DMR are methylated 
after paternal transmission, and the remaining DMRs are methylated after maternal transmission. The physical positions of examined DMRs are 
described in Table S3. Gray vertical bars indicate the reference ranges (minimum – maximum) in 50 control subjects. c Array-based genomewide 
copy-number and BAF analyses using CytoScan HD, and violin plot for the BAFs. d Microsatellite analysis using leukocyte (L) and saliva cells (S). In 
addition to single major peaks consistent with maternal isodisomy, minor peaks of non-maternal (paternal) origin are detected for three loci on four 
BAF band regions (written in blue), and those of maternal and non-maternal (paternal) origin are identified for the remaining three loci on six BAF 
band regions (written in red). Minor peaks of maternal and non-maternal (paternal) origin are indicated with red and blue asterisks, respectively. 
e Schematic representation of the generation of the parthenogenetic 46,XX cell lineage and the biparental 46,XX cell lineage. For simplicity, 
the behavior of single homologous chromosomes is shown, and all homologous chromosomes act similarly. The red and orange bars indicate 
homologous chromosomes in the oocyte, and the blue bar denotes a homologous chromosome in the sperm. M1, meiosis 1; M2, meiosis 2; PB-1, 
first polar body; PB-2, second polar body; and ER, endoreplication
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with single major microsatellite peaks of maternal origin 
and two minor microsatellite peaks of maternal and non-
maternal (paternal) origin (Additional file 1: Fig. S2). The 
usefulness of SNP array in the elucidation of generation 
mechanisms of such rare conditions has been reported 
previously [4, 6]. Indeed, CytoScan HD analysis has con-
firmed the underlying generation mechanisms in the 
previously reported parthenogenetic and androgenetic 
mosaic patients (Additional file 1: Figs. S3 and S4) [5, 7].
Several findings are notable with regard to the parthe-
nogenetic mosaicism of this patient. First, the mosaic 
ratio estimated by microsatellite analysis was well con-
sistent with the BAFs obtained by SNP array (Additional 
file 1: Fig. S2). This would argue for the accuracy of the 
molecular studies employed in this study. Second, par-
thenogenetic cells accounted for the majority of leuko-
cytes, despite the apparently global negative selective 
pressure of the parthenogenesis [13]. This would primar-
ily be due to the bias in the human study. Indeed, genetic 
abnormalities would not be identified if they are barely 
present in leukocytes. In addition, parthenogenetic cells 
might be well preserved in several tissues of subjects 
with hitherto unknown specific genetic and environmen-
tal factors. Third, the mosaic ratio was similar between 
leukocytes and salivary cells. This would probably be 
co-incidental, because it was rather different between 
the two tissues in the previously reported patient (case 4 
in Table  1) [5]. Indeed, since adult saliva cells primarily 
consist of leukocytes of mesodermal origin and epithelial 
cells of ectodermal origin with a roughly similar fre-
quency [14], the mosaic ratio could be variable between 
the leukocytes and salivary cells.
To date, parthenogenetic mosaicism has been identi-
fied in six subjects including this patient (Table 1) [2–6]. 
Although clinical information remains fragmentary, they 
primarily exhibit growth failure with some SRS features 
including hemihypoplasia. This would primarily be con-
sistent with the occurrence of such phenotypes in upd(7)
mat, upd(11)mat, upd(14)mat, upd(16)mat, and upd(20)
mat [7, 15]. In this regard, hemihypoplasia would prob-
ably be due to laterality in the distribution of partheno-
genetic cells, and disorders of sex development in cases 
1 and 2 is explained by the co-existing 46,XY cell lineage. 
In addition, upd(15)mat might be relevant to the devel-
opment of several features such as growth failure, intel-
lectual disability, and hypotonia observed in Prader-Willi 
syndrome [16], although such non-specific features are 
also reported in SRS [8]. For our patient, it is notable 
that she exhibited SRS-compatible phenotype in infancy 
and central precocious puberty and truncal obesity in a 
later age. Since such phenotype is characteristic of Tem-
ple syndrome caused by upd(14)mat [17], this may sug-
gest an epi-dominant clinical effect of the chromosome 
14q32.2 imprinted region and a relatively high frequency 
of the parthenogenetic cells in tissues/organs related to 
the phenotype of this patient.
Notably, this patient had IH and a c.1403G>A:p.
(Arg468Gln) variant in PER2. PER2 is involved in the 
Fig. 2 The PER2 variant identified in this patient. a Structure of the PER2 protein and the position of the p.Arg468Gln. NES, nuclear export signal; 
PAS, PER-ARNT-SIM; CKIε, casein kinase Iε; NLS, nuclear localization signal; and CRY, cryptochrome. b Extreme rarity of the c.1403G>A variant in 
representative public databases and in-house database, and high pathogenicity of this variant predicted by different methods (for URLs, see 
Methods). c Electrochromatograms showing the maternally inherited c.1403G>A substitution (marked with red asterisks). Direct sequencing 
denotes that the area under curve is much larger for the variant (VT) ″A″ allele than for the wildtype (WT) ″G″ allele in the patient, while it is 
similar between the ″A″ and ″G″ alleles in the mother. d The position of PER2 on chromosome 2 and the frequency of the variant allele. PER2 is 
present on the four BAF band region, and the observed frequencies of the VT and WT alleles in PER2 are similar to the predicted frequencies of the 
VT and WT alleles in a gene on the four BAF band regions (see Additional file 1: Fig. S2). e Protein modelling analysis. Dashed green lines indicate 
hydrogen bonds. f Subcellular distribution analysis. Shown are representative subcellular distribution patterns of the GFP-labelled p.Arg468Gln-PER2 
protein, and the number of cells assessed as "N", "N + C", and "C" distribution patterns. DAPI, 4′,6-diamidino-2-phenylindole; N, nucleus-dominant 
distribution; N + C, both nuclear and cytoplasmic distribution; and C, cytoplasm-dominant distribution. g Simplified schematic representation of 
the circadian cycle [19, 20, 24, 25]. PER2 protein contains at least two functionally different phosphorylation sites: one hitherto unidentified site 
that primarily mediates proteasomal degradation (target site-1, dark orange) and the other site for the nuclear retention that is phosphorylated 
by CKIε (target site-2, dark green). Left part indicates the circadian cycle with WT-PER2 (highlighted with yellow). At the beginning of the circadian 
cycle (morning – midday), the CLOCK-BMAL1 heterodimer activates PER2 and CRY expressions by binding to their regulatory elements (E-box), and 
PER2 with phosphorylation at the target site-1 and CRY are exported to the cytoplasm. At the later phase of the circadian cycle (afternoon – early 
night), PER2 with phosphorylation at the both target sites-1 and -2 forms a heterodimer with CRY, and the PER2-CRY heterodimer is imported to the 
nucleus where it represses the transactivation function of the CLOCK-BMAL1 heterodimer for PER2 and CRY . At the end of the circadian cycle (late 
night), the repression function of the PER2-CRY heterodimer is decreased because of the degradation of PER2 with phosphorylation at the target 
site-1 in the cytoplasm. This permits the operation of the circadian rhythm. Right part indicates the circadian cycle with the p.Arg468Gln-PER2 
variant (highlighted with dark gray). In this case, it is predicted that nuclear export of PER2 and PER2-CRY heterodimer is compromised (indicated 
with thin red dotted arrows) because of the position of the variant at NES3, leading to a relative accumulation of the PER2-CRY heterodimer in 
the nucleus (shown with a red vertical arrow) and, consequently, a prolonged repression by the PER2-CRY heterodimer for the CLOCK-BMAL1 
transactivation function (indicated with thick red bars). This would decelerate the production of PER2 and CRY, leading to IH
(See figure on next page.)
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mammalian circadian clock system, together with cryp-
tochrome (CRY), circadian locomotor output cycles 
kaput (CLOCK), and brain and muscle Arnt-like pro-
tein 1 (BMAL1) [18–20]. PER2 and CRY are positively 
expressed by the CLOCK-BMAL1 heterodimer, and 
PER2 and CRY proteins are exported from the nucleus 
to the cytoplasm. Then, the PER2-CRY complex gen-
erated in the cytoplasm is imported into the nucleus to 
inhibit their own transcriptions by directly interacting 
with the CLOCK-BMAL1 complex. This feedback cycle 
underlies the circadian rhythm (Fig.  2g and its legend) 
[18–20]. In this context, the p.Arg468Gln-PER2 protein 
of this patient distributed more frequently in the nucleus 
than the WT-PER2 protein, consistent with the vari-
ant being present at NES3. This would have resulted in 
the reduced PER2 and CRY production via a prolonged 
repressing effect of the PER2-CRY dimer on the CLOCK-
BMAL1 complex, leading to the development of IH as a 
circadian rhythm disorder (Fig. 2g) [21]. In this context, 
since the mother heterozygous for the c.1403G>A:p.
(Arg468Gln) variant had no sleep-related phenotype, 
this variant would have a recessive effect. The presence 
of this extremely rare variant in a heterozygous condi-
tion in the gnomeAD_exome_EAS database would also 
support the recessive effect. It is likely, therefore, that the 
recessive effect of the c.1403G>A:p.(Arg468Gln) variant 
was unmasked in the parthenogenetic cells, and that par-
thenogenetic cells accounted for a considerable degree of 
cells in the sleep control region such as the suprachias-
matic nucleus [18]. Thus, the c.1403G>A:p.(Arg468Gln) 
variant would be regarded as a likely causative vari-
ant for the development of IH. In addition, since PER2 
exerts biological effects on multiple systems [20], the 
c.1403G>A:p.(Arg468Gln) variant might also be involved 
in the development of phenotypes other than IH, such as 
central obesity, of this patient.
Several matters would be worth pointing out for PER2. 
First, the subcellular distribution was not so markedly 
different, though significant, between the WT-PER2 and 
p.Arg468Gln-PER2 proteins. This would not be unex-
pected, because: (1) p.Arg468Gln was assessed to just 
mildly affect the local protein structure and hydrogen 
bonds (Fig. 2e); (2) p.Arg468Gln is an exchange between 
hydrophilic basic and polar amino acids, while hydropho-
bic amino acids (e.g., leucine and isoleucine) are likely 
to play a crucial role in the NES [22]; and (3) substitu-
tion of one leucine and one isoleucine residues at NES3 
with hydrophobic alanine residues has exerted a sig-
nificant but mild effect on the subcellular distribution as 
observed in this study (replacement of two leucine resi-
dues at NES1 and that of four leucine residues at NES2 
with alanine residues have markedly and mildly affected 
the subcellular distribution, respectively) [23]. It appears 
therefore, that such a relatively mild alteration in the 
subcellular distribution can cause a clinically recogniz-
able sleep phenotype. Second, a pathogenic p.Ser662Gly 
variant has been identified at the CKIε domain in a fam-
ily with dominantly inherited advanced sleep-wake phase 
disorder (ASWPD) [24]. In contrast to the p.Arg468Gln, 
the p.Ser662Gly has been implicated to cause premature 
nuclear export of the p.Ser662Gly-PER2 protein [19, 20, 
24, 25] (for details, see Additional file  1: Fig. S5). It is 
likely, therefore, that PER2 variants lead to different sleep 
phenotypes (IH and ASWPD), probably depending on 
the subcellular distribution pattern of the variant PER2 
proteins. Lastly, significant associations have been identi-
fied between multiple SNPs and various sleep-wake phe-
notypes (Additional file  1: Table  S2). This indicates that 
PER2 variants function not only as causative factors but 
also as susceptibility factors.
Conclusions
We identified the first case of parthenogenetic mosaicism 
that was generated via second polar body retention and 
unmasked a recessive PER2 variant for IH. This implies 
the presence of different generation mechanisms for par-
thenogenetic mosaicism and the unmasking of a mater-
nal recessive variant by parthenogenesis.
Methods
Primers
Primers used are shown in Additional file 1: Table S3.
Methylation analysis
Pyrosequencing was performed for 59 CpG sites at nine 
DMRs involved in the development of SRS and other 
human imprinting disorders, using bisulfite-treated leu-
kocyte gDNA samples. The procedure was as described 
in the manufacturer′s instructions (Qiagen). Subse-
quently, MIs were obtained using PyroMark Q24 (Qia-
gen). The data from 50 healthy subjects were utilized as 
references.
Genomewide array‑based analysis
CNV and BAF analyses were performed using CytoS-
can HD (ThermoFisher Scientific) harboring more than 
2.4 million CNV markers and approximately 750,000 
SNP markers. The log ratio and B-allele frequency were 
calculated using Rawcopy R package [26].  We selected 
CNVs larger than 100-kb, using log-ratio thresholds of 
> +0.2 for gains and < −0.3 for deletions, as suggested 
previously [26],  and these CNVs were annotated using 
AnnotSV (Annotation and Ranking of Human Structural 
Variations) (https:// www. lbgi. fr/ Annot SV/ runjob).  We 
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searched for known pathogenic CNVs and CNVs of 
unknown significance absent from multiple public data-
bases adopted in AnnotSV. CNVs located on segmental 
duplications were regarded as begin CNVs.  Violin plot 
for BAFs was made with snp.profile.Rdata by ggplot2 
(https:// ggplo t2. tidyv erse. org/ refer ence/ index. html).
Microsatellite analysis
PCR was performed with a fluorescently labeled for-
ward primer and an unlabeled reverse primer flanking 
each microsatellite locus. Subsequently, PCR prod-
ucts were determined for physical sizes and area under 
curves on an ABI PRISM 3100xl Genetic Analyzer 
using Gene Mapper software version 4.1 (ThermoFisher 
Scientific).
Whole exome sequencing
Whole exome sequencing was carried out using Sure-
Select Human All Exon V6 (Agilent Technologies). 
Captured libraries were sequenced by NextSeq 500 
(Illumina) with 150  bp paired-end reads. Exome data 
processing, variant calling, and variant annotation 
were carried out, as described previously [27]. Human 
GRCh37 was utilized as the reference genome, and the 
PER2 variant was described according to the HGVS 
recommendations [28], using NM_022817.2 as the ref-
erence sequence (https:// www. ncbi. nlm. nih. gov/ genba 
nk). We extracted rare variants with minor allele fre-
quencies of < 0.005 in all the following public databases 
and in-house database (n = 218): (1) whole genome 
and exome data for East Asian Population in Genome 
Aggregation Database (gnomAD_genome_EAS and 
gnomAD_exome_EAS) (http:// gnomad. broad insti tute. 
org/); (2) Human Genetic Variation Database (HGVD) 
(http:// www. hgvd. genome. med. kyoto-u. ac. jp/); and 
(3) whole-genome sequences of 8380 healthy Japanese 
individuals and construction of the highly accurate 
Japanese population reference panel (8.3KJPN) (https:// 
ijgvd. megab ank. tohoku. ac. jp/). Final variants were 
annotated with Annovar [29].
In silico pathogenicity predictions were carried out 
for identified rare variants, using the following meth-
ods: (1) CADD (Combined Annotation–Dependent 
Depletion) (http:// cadd. gs. washi ngton. edu/); (2) PP2_
HVAR (Polyphen-2 Hum Var) (http:// genet ics. bwh. 
harva rd. edu/ pph2/); (3) SIFT (Sorting Intolerant From 
Tolerant) (http:// sift. jcvi. org/); and (4) MutationTaster 
(http:// www. mutat ionta ster. org/). We further examined 
the involvement of genes with rare variants in the circa-
dian rhythm [12].
Sanger sequencing
Sanger direct sequencing was performed for PCR prod-
ucts containing identified variants on the ABI 3130xl 
Genetic Analyzer (ThermoFisher Scientific). To confirm 
the variant, the PCR products were subcloned with the 
TOPO TA Cloning Kit (ThermoFisher Scientific), and 
wildtype and variant alleles were sequenced separately.
Protein modelling analysis
The impact of p.Arg468Gln on protein structure was 
examined for mouse crystal structure of a PAS domain 
fragment (Protein Data bank ID code: 3GDI) using 
Swiss PDB Viewer. The 468th Arg codon in the human 
corresponds to the 466th Arg codon in the mouse.
Subcellular distribution analysis
Full-length wildtype PER2 cDNA (WT-PER2) embed-
ded in pF1K0F vector was obtained from Kazusa DNA 
Research Institute (Product ID FXC06329), and variant 
PER2 cDNA with c.1403G>A (c.1403G>A-PER2) was 
created by site-directed mutagenesis using PrimeSTAR 
Mutagenesis Basal Kit (Takara Bio). cDNAs for the WT-
PER2 and c.1403G>A-PER2 were fused to the C-terminal 
side of the GFP gene in pEF1α-EGFP vector. Transfection 
was performed for COS7 cells, which were seeded into 
6-well dishes containing 3 mL of DMEM with 10% fetal 
bovine serum (3.0 ×  105 cells/well) and were maintained 
for 24 h, using lipofectamine 3000 (ThermoFisher Scien-
tific). Transfected COS7 cells were further cultured for 
24  h, and fluorescent signals were obtained using ZOE 
Fluorescent Cell Imager (Bio-Rad) with and without the 
4,6 diamidino-2-phenylindole (DAPI) staining. Subcel-
lular distribution patterns were evaluated as a nuclear 
localization pattern (N), a nuclear-cytoplasmic distri-
bution pattern (N + C), and a cytoplasmic localization 
pattern (C) by a technician who did not know the pur-
pose of this experiment. The experiments were repeated 
six times, and a total of ~ 2000 cells were observed 
for the subcellular distribution of the WT-PER2 and 
p.Arg468Gln-PER2 proteins. Statistical analysis of the 
subcellular distribution pattern between the WT-PER2 
and p.Arg468Gln-PER2 proteins (2 × 3 contingency 
table) was performed with the two-tailed Fisher’s exact 
probability test.
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